The Plymouth Student Scientist
Document Type
Biomedical and Healthcare Sciences Articles
Abstract
The oral antidiabetic, metformin, has been documented to have antineoplastic activity in various cancer cell lines, associated with the inhibition of mitochondrial complex I. However, pre-clinical studies have struggled to demonstrate such antineoplastic activity utilising metformin concentrations attainable with standard antidiabetic dosing. Research has revealed that metformin combined with the anti-hypertensive drug, syrosingopine, lowers metformin’s therapeutic threshold and sensitizes cancer cells to killing, by inhibiting monocarboxylate transporters (MCT)1/MCT4. The potent interaction between these drugs elicits a synthetic lethality, specific to transformed cells. This preliminary study aimed to investigate metformin’s antineoplastic effects and its synergistic relationship with syrosingopine by measuring cell viability and extracellular lactate in PC3 (adherent) and THP-1 (suspension) cancer cell lines. Overall, the PC3 cell line responded better to treatment with combined doses of metformin and syrosingopine, or either drug alone; however, synthetic lethality was not observed in either cell line. In both cell lines, the interaction between metformin and syrosingopine was not statistically significant in the cell viability assays (p>0.05). Analysis of MCT1/MCT4 inhibition through the measurement of extracellular lactate was not statistically significant (p>0.05) and proved inconclusive. Additionally, the nature of the cell line, adherent or suspension, was statistically significant (p<0.05) in some treatment groups, suggesting that this may play a role in the efficacy of the drug treatments. Further research is necessary to better understand the underlying cellular mechanisms of metformin and syrosingopine’s synthetic lethality, and syrosingopine’s MCT1/MCT4 inhibition. Future research should focus on achieving metformin doses capable of exhibiting antineoplastic effects in vivo.
Publication Date
2022-07-28
Publication Title
The Plymouth Student Scientist
Volume
15
Issue
1
First Page
1
Last Page
22
ISSN
1754-2383
Deposit Date
July 2022
Embargo Period
2024-07-08
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Medeiros, Sophia V.
(2022)
"Investigating Metformin & Syrosingopine's Synthetic Lethality in PC3 & THP-1 Cancer Cell Lines,"
The Plymouth Student Scientist: Vol. 15:
Iss.
1, Article 3.
DOI: https://doi.org/10.24382/6qvr-w034
Available at:
https://pearl.plymouth.ac.uk/tpss/vol15/iss1/3